Taysha Gene Therapies (TSHA) Interest & Investment Income (2021 - 2026)

Taysha Gene Therapies has reported Interest & Investment Income for 4 years, with the latest figure at $2.6 million in Q1 2026.

• Quarterly Interest & Investment Income rose 95.02% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 59.5% YoY) and the FY2025 annual result came in at $9.2 million, up 32.91% from the prior year.
• Interest & Investment Income eased to $2.6 million in Q1 2026 per TSHA's latest filing, from $2.9 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $3.2 million in Q3 2025 and troughed at $1.1 million in Q3 2023.
• A 4-year average of $2.0 million and a median of $1.9 million in 2025 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2025 and 2026: Interest & Investment Income dropped 21.68% in 2025, then jumped 95.02% in 2026.
• Over 4 years, Interest & Investment Income stood at $1.9 million in 2023, then slipped by 11.5% to $1.7 million in 2024, then surged by 68.82% to $2.9 million in 2025, then decreased by 9.9% to $2.6 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $2.6 million, $2.9 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.